Audit in process? Call the number on your audit letter to get options.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
September 30, 2016 – The FDA announced the discontinuation of Novartis’ Tyzeka (telbivudine) 600 mg tablets.
Download PDF
Return to publications
